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Background  and  purpose:  An early  diagnosis  is  essential  for therapeutic  decision  and  risk  stratiﬁcation  in
patients with  suspected  acute  myocardial  infarction  (AMI).  We  analyzed  and  compared  the  diagnostic
value  of  high-sensitivity  troponin  T (hs-TnT)  and other  cardiac  markers  in patients  with  an  initially
negative  troponin  T  test  at presentation.
Methods  and subjects:  The  present  study  was  a  prospective,  multicenter  study  including  ﬁve participating
emergency  cardiovascular  tertiary  centers  in  Japan.  From  November  2009  through  January  2011,  patients
with suspected  AMI  at  the  emergency  room  with  an  initial  troponin  T (c-TnT)  test  <100  ng/L  were  enrolled.
Results:  A  total  of  85 patients  were  prospectively  assigned  from  ﬁve  participating  emergency  cardiovascu-
lar tertiary  centers  in Japan.  The median  time  from  the  onset  of  chest  pain  to  the T0 sampling  was  165 min
[IQR  120–180].  The  ﬁnal  diagnoses  according  to  the  recent  universal  deﬁnition  and  other  standard  cut-off
values  were  AMI in 47, unstable  angina  in  12, and  non  AMI  in 38 patients.  The  overall  ROC-AUC  value
of  hs-TnT,  c-TnT,  creatine  kinase  MB,  and  heart-type  fatty  acid-binding  protein  were  0.810,  0.716,  0.782,
and  0.880,  respectively.  The  diagnostic  sensitivity  and  negative  predictive  value  of hs-TnT  were  both
100%  for  the  patients  admitted  more  than  120  min  from  the  onset,  however  the  speciﬁcity  was  limited
for  the  whole  time-windows  (71%).  The  absolute  value  change  of  the  hs-TnT  from  T0  to  T3  sampling  3 h
later  improved  the  ROC-AUC  up  to  0.972  and  the  speciﬁcity  was  92%  at 22 ng/L  (ROC-optimized  cut-off)
and  100%  at 105 ng/L  (rule-in  cut-off).
Conclusions:  The  hs-TnT  displayed  100%  sensitivity  and  negative  predictive  value  for the patients  admitted
more than  120  min  from  the  onset,  however  the  speciﬁcity  was  limited.  The  absolute  change  from  T0  to
e  tota
3  JapT3 (22  ng/L)  improved  th
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An early diagnosis is of absolute necessity for appropriate ther-
peutic decision-making and risk stratiﬁcation in patients with
cute coronary syndrome (ACS). Cardiac troponin (TnT) measure-
ent has become essential in the diagnosis of acute myocardial
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infarction (AMI) according to the European Society of Cardi-
ology (ESC)/American College of Cardiology (ACC) Task Force
redeﬁnition of myocardial infarction [1]. Moreover, as the Joint
ESC/ACC/American Heart Association/World Heart Federation Task
Force presented in the universal deﬁnition of myocardial infarction
in 2007 [2], the diagnosis of AMI  is accurately determined based
on a rise and/or fall in cardiac biomarkers with at least one value
above the 99th percentile of the upper reference limit (URL). In
these statements, troponin measurements were preferable to other
markers and the optimal precision at the 99th percentile URL was
deﬁned as a coefﬁcient of variation (CV) <10%. Conventional TnT
(c-TnT) testing has been widely available, however, the accuracy
vier Ltd. All rights reserved.

























































Fig. 1. Flow chart of patient enrollment in the HsTnT-iNET study. AMI, acute myocar-M. Kitamura et al. / Journal 
s not satisfactory at lower concentrations <100 ng/L which is
equired for an early diagnosis of AMI  [3]. The novel high-sensitivity
ardiac troponin T (hs-TnT) assay fulﬁlls this optimal precision at
he 99th percentile URL (CV 9% at 13.5 ng/L), and it is therefore
xpected to become the new standard for diagnosing AMI  [3].
Regarding the treatment of cardiac emergencies, the prevalence
f AMI  varies in each clinical setting, such as among local medical
linics, emergency rooms in general hospitals, and tertiary cen-
ers equipped with coronary care units. In the latter situation, the
revalence would be higher, especially for patients referred from
mergency services. Moreover, the therapeutic strategy for ACS and
he mortality of AMI in the tertiary medical center have varied over
ecent decades [4–6].
A population study based on real-world clinical practice has thus
een warranted to investigate diagnostic performance of biomark-
rs. Therefore, we conducted a prospective, multicenter study to
valuate the diagnostic performance of hs-TnT and other cardiac
arkers in populations with highly suspected AMI. The present
tudy especially focused on the diagnostic performance of hs-TnT
n patients with an initially negative c-TnT test on arrival.
ethods
tudy design and population
The present high-sensitivity cardiac Troponin T for earlier diag-
osis of acute myocardial infarction in patients with an initially
egative troponin T test (HsTnT-iNET) study, was a prospec-
ive multicenter study including ﬁve participating tertiary centers
quipped with coronary care units in Japan. From November 2009
hrough January 2011, patients who presented at the emergency
oom with symptoms suggestive of AMI, were enrolled in the
resent study. This study was conducted according to the princi-
les of the Declaration of Helsinki and the protocol was approved
y the ethics committee at each participating institution. Written
nformed consent was obtained from all patients in the emergency
oom.
Blood samples were drawn during the acute phase, namely,
t presentation (T0), 3 h (T3), and 6 h (T6) after the T0 samp-
ing. At the ﬁrst sampling (T0), a whole-blood rapid TnT test was
imultaneously performed to exclude TnT-positive patients for
he enrollment. If the rapid TnT test was positive (indicated as
-TnT ≥ 100 ng/L) at presentation (T0), then the later samplings
T3 and T6) were not performed. T0 and T3 samplings were used
or analysis of the diagnostic performances. T6 sampling was
sed for adjudicating AMI  diagnosis to determine whether serum
yocardial enzyme signiﬁcantly increased. Immediately after cen-
rifugation, the sample serum was stored at −80 ◦C until each
easurement was performed.
Baseline T0 measurements were available from 113 patients at
he ﬁve participating sites. We  excluded 4 patients who arrived
ore than 24 h from the onset of symptoms and 24 patients with
n initially positive c-TnT test (≥100 ng/L) at presentation. A total
f 85 patients with an initially negative c-TnT test were assigned to
he HsTnT-iNET study (Fig. 1).
The levels of c-TnT, creatine kinase MB  isozyme (CK-MB), myo-
lobin, and N-terminal B-type natriuretic peptide (NT-proBNP)
ere measured by an electrochemiluminescence immunoas-
ay (ECLIA) with the Roche Modular Analytics E170® (Roche,
asel, Switzerland). Hs-TnT was measured by an ECLIA with the
CLusys®/Elecsys® hs-TnT 2010 Roche diagnostics assay. The ana-
ytical characteristics of the troponin assays have been reported
t http://www.ifcc.org. In the c-TnT assay, the 99th percentile of
he URL, %CV at the 99th percentile, and the value with a 10%
V were calculated to be 10 ng/L, 18% and 30 ng/L, respectively.dial infarction; AP, angina pectoris; CSA, coronary spastic angina; NSTEMI, non-ST
elevation myocardial infarction; STEMI, ST elevation myocardial infarction; TnT,
troponin T.
Therefore, the cut-off value for a diagnosis of AMI was deﬁned as
30 ng/L because the precision was unsatisfactory at the 99th per-
centile. In the CK-MB assay, the 97.5th percentile of the URL was
reported to be 3.1 ng/mL, and the %CV at 8.2 ng/mL was calculated
to be 3.1%. Generally, 5.0 ng/mL had been used as the cut-off value of
CK-MB for the diagnosis of AMI, which fulﬁlled required analytical
precision. The serum concentration of heart type fatty acid-binding
protein (H-FABP) was measured by an enzyme-linked immunosor-
bent assay (ELISA).
The cut-off values of hs-TnT, c-TnT, CK-MB, and H-FABP were
deﬁned as 14 ng/L (the value at 99% URL), 30 ng/L (the value for
10% CV), 5.0 ng/L, and 6.2 ng/L. The values of CK-MB and H-FABP had
been used as the cut-off point to diagnose MI  in clinical practice.
To clarify the impact of time from onset to presentation for the
diagnostic performances of the novel cardiac biomarkers, we  pre-
sented the results with stratiﬁcation of the study population into
three time-windows of ≤2 h, 2–4 h, and >4 h from the onset.
Adjudication of the ﬁnal diagnosis
To determine the ﬁnal diagnosis for each patient, all case records
collected from all participating institutes were reviewed, regarding
the clinical diagnosis, coronary risk factors, time course from the
onset of symptoms to presentation, ﬁndings of electrocardiogra-
phy (ECG), coronary angiography (CAG), and other examinations
and all medical treatments. The diagnosis of AMI  was determined
according to the universal deﬁnition of MI  [2]. In brief, the deﬁnition
requires detection of a rise and/or fall in TnT together with evidence
of myocardial ischemia. Signiﬁcant increase in c-TnT for the diagno-
sis of AMI  was  deﬁned as 30 ng/L during T0–T6 and speciﬁc ﬁndings
of myocardial ischemia were described as chest symptoms last-
ing over 20 min, ECG changes (new ST-T changes, new left bundle
branch block, or development of pathological Q waves) and imag-
ing of viability loss of the myocardium or new regional wall motion
abnormality. Importantly, myocardial injury due to other clinical
causes was  carefully ruled out.
The classiﬁcation by ST-T deviation was  performed based on
the raw data of ECG and the declared diagnosis from the partici-
pant institution. ST-segment elevation MI (STEMI) was  deﬁned as
ischemic myocardial injury with ST-segment elevation (>0.1 mV)
on more than 2 contiguous leads.
In patients with non ST-segment elevation MI  (NSTEMI) who
received percutaneous coronary intervention (PCI) before the sec-
ond blood sampling, the cut-off point of c-TnT was deﬁned as three
times the 99th percentile URL (90 ng/L), because myocardial injury
could not be discriminated between AMI  and peri-procedural
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nd then this ﬁnal diagnostic criterion conformed to the universal
eﬁnition of MI  [2].
Coronary spastic angina (CSA) was diagnosed for the patients
ith resting chest pain in the situations of no signiﬁcant organic
tenosis explaining AMI  or appearance of transient coronary nar-
owing (>75%) proved by CAG with or without provocation agent
acetylcholine or ergonovine) [7]. We  basically adopted the ﬁnal
iagnosis declared from the participating institution, if there was
o discrepancy between the diagnosis and the collected clinical
ndings.
nterventional procedures
Emergency CAG was performed if necessary to assess the
natomical ﬁndings of coronary culprit lesion and to make ther-
peutic decisions. Intervention procedures for reperfusion were
elected at operator’s discretion, including thrombectomy, balloon
ilatation, stent implantation, and distal protection. Temporary
acing and intra-aortic balloon pumping were available if neces-
ary.
tatistical analysis
Continuous variables are presented as the means (±standard
eviation) or medians [the interquartile range]. Categorical vari-
bles are presented as numbers and percentages. The diagnostic
erformances of each assay were represented as the sensitiv-
ty, speciﬁcity, positive predictive value (PPV), negative predictive
alue (NPV), and receiver operating characteristics (ROC) curve
ith the area under the curve (AUC), presented together with
able 1
aseline characteristics of study population.
All patients (N = 85)
Age (years) 
Median 67 
IQR  51–74 
Male  sex – no (%) 66 (78) 
Risk  factors – no (%)
Hypertension 58 (68) 
Dyslipidemia 46 (54) 
Diabetes 23 (27) 
Current smoking 30 (35) 
History, n (%) 
Coronary artery disease 21 (25) 
Previous MI 6 (7) 
Previous PCI 10 (12) 
Previous CABG 5 (6) 
Status  of arrival, n (%) 
Walk-in 16 (19) 
EMS  65 (76) 
Helicopter EMS  5 (6) 
Referral from other clinic 17 (20) 
Time from onset of chest pain (min) 
Median 165 
IQR  120–180 
Electrocardiographic ﬁndings at presentation, n (%) 
ST-segment elevation 48 (56) 
ST-segment depression 13 (15) 
T-wave inversion 8 (10)
Abnormal Q wave 11 (13) 
No  signiﬁcant ﬁnding 16 (19) 
eGFR  (mL/min) 
Median 76 
IQR  60–88 
<60  mL/min, n (%) 20 (24) 
<30  mL/min, n (%) 2 (2) 
I,  myocardial infarction; EMS, Emergency Medical Service; eGFR, estimated glomeru
umping; PCPS, percutaneous cardiopulmonary support; PCI, percutaneous coronary int
pastic angina; IQR, interquartile range.diology 62 (2013) 336–342
the 95% conﬁdential interval (95%CI) or ±standard error. Compar-
isons between biomarkers were performed by an analysis of the
differences of the diagnostic performances with McNemar’s test,
Fisher’s exact test or Pearson’s chi-square test, as appropriate. The
statistical analysis of differences between the ROC-AUC of each
biomarker was  performed using the method reported by Hanley
and McNeil [8]. These analyses of differences between biomarkers
were adjusted by Bonferroni’s correction within each time-window
group. The rule-in cut-off was  deﬁned as the cut-off point achieved
with a 100% PPV (i.e. 100% speciﬁcity). In the analysis of changes
between T0 and T3, ROC-optimized cut-off and rule-in cut-off
values were presented, and the diagnostic performances at both
cut-off values were calculated. The statistical analyses were per-
formed using the SPSS software program version 16.0.2 (SPSS Inc.,




The characteristics of the patients and the details of diagnosis are
presented in Table 1. Thirty-seven patients were classiﬁed as hav-
ing STEMI and 10 as having NSTEMI. Type 4a MI  was not detected in
the present study population. There were 41 patients (48%) in Killip
class I, 3 (4%) in class II, and 3 (4%) in class III. The median age was
67 years [IQR 51–74]. The median time from the onset of symp-
toms to drawing of T0 blood sample was  165 min  [IQR 120–180].
Ischemic ST-T ﬁndings of ECG were observed in 69 patients (81%)
at presentation, with ST-segment elevation being most frequently
Pharmacological therapy, n (%)
Antiplatelet 77 (92)
Anticoagulant 70 (83)
Thrombolytic agent 0 (0)
Nitrates 34 (41)
Beta blocker 22 (26)
RAA blocker 35 (42)
Ca channel blocker 17 (20)
IV-Nicorandil 40 (48)
IV-Inotropes 9 (11)




Invasive procedure, n (%)
Coronary angiography 74 (87)
PCI 50 (59)
CABG 0 (0)
Final diagnosis, n (%)





Class II 3 (4)
Class III 3 (4)
Class IV 0 (0)
Non-AMI 38 (45)
Unstable AP 12 (14)
Stable AP 2 (4)
CSA 12 (13)
Other cardiac 3 (4)
Non-cardiac 6 (7)
Unknown 3 (4)
lar ﬁltration rate; RAA, renin–angiotensin–aldosterone; IABP, intraaortic balloon
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etected (n = 48; 56%) and a normal ECG was observed in 16 patients
19%). The details of treatments within 48 h from presentation are
hown in Table 1.
iagnostic performance of cardiac markers with stratiﬁcation by
he time from onset
The diagnostic performance of each biomarker is described with
tratiﬁcation by time from onset to admission in Table 2. The
ensitivities within 120 min  from onset were low for all mark-
rs, however that of hs-TnT was 100% in the time-window after
20 min  from onset. The overall sensitivity of hs-TnT was  signiﬁ-
antly higher than that of c-TnT (p < 0.001) and CK-MB (p < 0.001),
nd similar to that of H-FABP. However, the overall speciﬁcity of hs-
nT was signiﬁcantly lower than that of the other cardiac markers
p < 0.05).
The distribution of cardiac marker levels in T0 samples and the
ime from onset in AMI  patients (n = 47) are shown in Fig. 2A–D. All
MI patients admitted more than 2 h from the onset showed pos-
tive results in the hs-TnT measurements, with a cut-off value of
4 ng/L. Meanwhile, all hs-TnT negative AMI  patients (n = 12) were
istributed in the time-window with admission earlier than 2 h
rom the onset.
The ROC-AUC of the hs-TnT, c-TnT, and CK-MB increased with
ime, while that of the H-FABP later than 4 h after the onset showed
 tendency to be reduced (Fig. 3). The overall ROC-AUC of the hs-
nT, c-TnT, CK-MB, and H-FABP were 0.810, 0.716, 0.782, and 0.880,
espectively. However, there were no statistically signiﬁcant dif-
erences among the validated cardiac markers at the ﬁrst sampling
T0).
The distribution of measurements of each cardiac marker were
ompared with those of hs-TnT (Fig. 4A–C). Among 31 negative
-TnT patients having AMI, 12 patients (61%) were positive for
s-TnT (Fig. 4A). Out of 12 negative hs-TnT patients having AMI,
nly 4 cases were positive for H-FABP, while the others (n = 8)
able 2
omparisons of the diagnostic performances among the validated cardiac biomarkers.
Within 2 h 2–4 h
n  = 30 n = 33
Number (%) of AMI  16 (53) 25 (7
High-sensitivity troponin T (hs-TnT)
Sensitivity 25% (7–52) 100%
Speciﬁcity 57% (29–82) 75% (
PPV 40% (12–74) 93% (
NPV  40% (19–64) 100%
Conventional troponin T (c-TnT)
Sensitivity 19% (4–46) 48% (
Speciﬁcity 93% (66–100) 100%
PPV  75% (19–99) 100%
NPV  50% (30–70) 38% (
Creatine kinase MB  isozyme (CK-MB)
Sensitivity 6% (0–30) 52% (
Speciﬁcity 93% (66–100) 88% (
PPV 50% (1–99) 93% (
NPV  46% (28–66) 37% (
Heart type fatty acid-binding protein (H-FABP)
Sensitivity 38% (15–65) 88% (
Speciﬁcity 93% (66–100) 75% (
PPV  86% (42–100) 92% (
NPV  57% (34–77) 67% (
* p < 0.05 in comparison with that of hs-TnT.
** p < 0.01 in comparison with that of hs-TnT.
*** p < 0.001 in comparison with that of hs-TnT.
† p < 0.05 in comparison with that of H-FABP.
†† p < 0.01 in comparison with that of H-FABP.diology 62 (2013) 336–342 339
were negative for both hs-TnT and H-FABP (Fig. 4C) at presentation
(T0). Moreover, in an evaluation of the combination of hs-TnT and
H-FABP, the sensitivity, speciﬁcity, PPV, and NPV were 83% (95%CI;
69–92), 71% (54–85), 78% (64–88), and 77% (60–90).
There were 18 patients (21%) with renal function disturbance
of estimated glomerular ﬁltration rate <60 mL/min, all had coro-
nary artery disease (AMI, n = 15; unstable angina pectoris, n = 2;
CSA, n = 1). The non-AMI patients with positive hs-TnT (≥14 ng/mL)
were diagnosed with unstable angina pectoris (n = 2) and CSA
(n = 1). Meanwhile, there were 3 patients with negative hs-TnT
(<14 ng/mL), and they were all diagnosed with STEMI within
120 min  from onset.
Diagnostic performances of changes in cardiac markers from T0 to
T3
Consecutive acquisitions of T0–T6 samples were completed
in 82 patients and 46 patients (56%) were diagnosed with AMI.
The ROC curves of all cardiac markers are described in Fig. 5.
The ROC-optimized cut-off and rule-in cut-off and the diagnos-
tic performances at both cut-offs changes are shown in Table 3.
The ROC-optimized cut-off of the relative and absolute change
in the hs-TnT between T0 and T3 were 105% and 22 ng/L, and those
of the absolute changes in the c-TnT, CK-MB, and H-FABP were
15 ng/L, 0.8 ng/mL, and 3.7 ng/mL. Moreover, the rule-in cut-off val-
ues of the relative and absolute changes were 142% and 105 ng/L,
and those of the absolute changes in c-TnT, CK-MB, and H-FABP
were 85 ng/L, 2.1 ng/mL, and 105 ng/mL, respectively (Table 3). At
the rule-in cut-off of the change, the sensitivity of the absolute
change in H-FABP was the lowest (54%) compared with the other
cardiac markers, and the cut-off change (105 ng/mL) was much
higher than the ROC-optimized cut-off. The overall ROC-AUCs of the
changes in all cardiac markers are shown in Table 3. The absolute
change in hs-TnT showed the highest ROC-AUC among all values,
% (95% conﬁdential interval)
After 4 h All
 n = 22 n = 85
6) 6 (27) 47 (55)
 (86–100)** 100% (54–100) 74% (60–86)***
35–97) 81% (54–96) 71% (54–85)*
76–99) 67% (30–93) 76% (61–87)
 (54–100) 100% (75–100) 69% (52–83)
28–69)**,† 17% (0–64) 34% (21–49)***,††
 (63–100) 100% (79–100) 97% (86–100)
 (74–100) 100% (3–100) 94% (71–100)
18–62) 76% (53–92) 54% (42–67)
31–72)**,† 50% (12–88) 36% (23–51)***,††
47–100) 100% (79–100) 95% (82–99)*
66–100) 100% (29–100) 89% (67–99)
16–62) 84% (60–67) 55% (42–67)
69–97)† 50% (12–88) 66% (51–79)††
35–97) 100% (79–100) 92% (79–98)
73–99) 100% (29–100) 91% (76–98)
30–93) 84% (60–97) 69% (52–81)
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Fig. 2. (A–D) Distribution of cardiac marker levels at ﬁrst drawn sampling (T0) and time fr
of  high-sensitivity troponin T (hs-TnT) (A), conventional troponin T (c-TnT) (B), creatine k
(D).
Fig. 3. ROC-AUC of the validated cardiac markers with stratiﬁcation by time from
onset. hs-TnT, high-sensitivity troponin T; c-TnT, conventional troponin T; CK-MB,
creatine kinase MB  isozyme; H-FABP, heart type fatty acid-binding protein.om onset in acute myocardial infarction patients were described by measurements
inase MB isozyme (CK-MB) (C), and heart type fatty acid-binding protein (H-FABP)
however, there was  no statistically signiﬁcant difference between
the values.
Discussion
The excellent diagnostic performance of hs-TnT assays has been
reported in several studies for various populations. Reichlin et al.
reported the results of a prospective multicenter study of hs-TnT for
the early diagnosis of AMI  [9], in which the prevalence of AMI was
one sixth of the population and three-quarters of patients had nor-
mal  ECG. Giannitsis et al. reported that the diagnostic performance
of hs-TnT for NSTEMI in a population with a high prevalence of ACS
was as high as 85% [3,10]. Their reports demonstrated that hs-TnT
measurements were useful for an earlier diagnosis of AMI espe-
cially for patients without ST-segment elevation to discriminate
NSTEMI from unstable angina pectoris. However, the diagnostic
performance seemed to be overestimated by the exclusion of STEMI
because the arrival time from onset in STEMI patients is frequently
shorter than that in NSTEMI patients [11].Comparisons with previous investigations
In comparison with previous reports from Western countries
[9,10,12–14], the prevalence of abnormal ECG, AMI, and STEMI was
M. Kitamura et al. / Journal of Cardiology 62 (2013) 336–342 341
Fig. 4. (A–C) Comparison between hs-TnT and other cardiac markers [c-TnT (A), CK-MB (
troponin T; c-TnT, conventional troponin T; CK-MB, creatine kinase MB  isozyme; H-FABP
Fig. 5. ROC curves of changes from T0 to T3. hs-TnT, high-sensitivity troponin T;
c-TnT, conventional troponin T; CK-MB, creatine kinase MB isozyme; H-FABP, heart
type fatty acid-binding protein.
Table 3
Diagnostic performances of changes in the validated cardiac biomarkers.
Cut-off value Sensitivity Speciﬁ
Relative change in hs-TnT (T3-T0)
ROC-optimized cut-off 105% 91% (79–98) 94% (8
Rule-in cut-off 142% 89% (76–96) 100% (
Absolute change in hs-TnT (T3-T0)
ROC-optimized cut-off 22 ng/L 91% (79–98) 92% (7
Rule-in cut-off 105 ng/L 83% (69–92) 100% (
Absolute change in c-TnT (T3-T0)
ROC-optimized cut-off 15 ng/L 91% (79–98) 92% (7
Rule-in cut-off 85 ng/L 83% (69–92) 100% (
Absolute change in CK-MB (T3-T0)
ROC-optimized cut-off 0.8 ng/mL 89% (76–96) 94% (8
Rule-in cut-off 2.1 ng/mL 87% (74–95) 100% (
Absolute change in H-FABP (T3-T0)
ROC-optimized cut-off 3.7 ng/mL 89% (76–96) 83% (6
Rule-in cut-off 105 ng/mL 54% (39–69) 100% (
hs-TnT, high-sensitivity troponin T; c-TnT, conventional troponin T; CK-MB, creatine k
predictive value; NPV, negative predictive value; ROC, receiver-operator characteristics; B) and H-FABP (C)] in acute myocardial infarction patients. hs-TnT, high-sensitivity
, heart type fatty acid-binding protein.
higher in the present study. The diagnostic performances of hs-TnT
were similar to previous studies in suspected AMI  patients with
an initially negative c-TnT [10,13,14], but lower if compared with
the report by Reichlin et al. [9], which showed the excellent diag-
nostic values of hs-TnT (ROC-AUC: 0.96). The conceivable causes
were the differences in entry criteria. First, excluding initial posi-
tive c-TnT patients would reduce the ROC-AUC and the prevalence
of positive hs-TnT patients. In fact, after the exclusion of positive
c-TnT cases, the ROC-AUC of hs-TnT was  reduced from 0.949 to 0.81
in the study by Weber et al. [14]. Second, the prevalence of AMI  in
the present study was  much higher than that in Reichlin’s report,
which displayed the excellent diagnostic performance of hs-TnT
in a chest pain unit. Indeed, the PPV was reduced by increasing
the false-positive cases in the chest pain unit situation because the
prevalences of AMI  patients and those of abnormal ECG changes
were lower (17% and 27%, respectively). Third, the time from the
onset to the entry was shorter than that in other studies. In the pre-
vious study by Weber et al. the patients had been admitted much
later after the onset [the median (IQR) was  7 h (3–15)]. The advan-
tage of using hs-TnT over c-TnT would decrease as time passed
(ROC-AUC: 0.949 in hs-TnT and 0.929 in c-TnT) [14].
Comparisons with other cardiac biomarkersIn our study, the absolute change in the hs-TnT showed the most
powerful diagnostic value in the evolving phase within 3 h after
admission, and using the rule-in cut-off change after repeating the
(95% conﬁdential interval)
city PPV NPV ROC-AUC
1–99) 95% (85–99) 89% (75–97) 0.947 (0.895–0.998)
90–100) 100% (91–100) 88% (74–96)
8–98) 93% (82–99) 89% (75–97) 0.973 (0.945–1.000)
90–100) 100% (91–100) 82% (67–92)
8–98) 93% (82–99) 89% (75–97) 0.966 (0.926–1.000)
90–100) 100% (91–100) 82% (67–92)
1–99) 95% (84–99) 87% (73–96) 0.924 (0.858–0.990)
91–100) 100% (91–100) 86% (71–95)
7–94) 87% (74–95) 86% (70–95) 0.928 (0.874–0.981)
90–100) 100% (86–100) 63% (49–76)
inase MB  isozyme; H-FABP, heart type fatty acid-binding protein; PPV, positive





































































metalloproteinase-9 for the earliest stage acute coronary syndrome. Circ J
2011;75:2853–61.42 M. Kitamura et al. / Journal 
s-TnT after 3 h could diagnose AMI  with a speciﬁcity as high as
00%. Reichlin and Aldous et al. validated the utility of the absolute
hange of the hs-TnT within 2 h to discriminate AMI  [15,16]. Their
ndings were consistent with ours in that the isolated application of
he ﬁrst hs-TnT measurement might be insufﬁcient because of the
ower speciﬁcity, and that it should be used as a rule-in or rule-out
ethod depending on the clinical situations.
The overall diagnostic sensitivity of hs-TnT and H-FABP were
omparable and both were signiﬁcantly superior to those of c-TnT
nd CK-MB. Notably, the ROC-AUC and the sensitivity of H-FABP
ithin 120 min  from the onset were the highest, however, these
alues decreased as time passed. Previous reports demonstrated
hat the results of the H-FABP resembled those of myoglobin, but
hey were more speciﬁc for myocardial injury and proved to be
seful in the early diagnosis of AMI  [17–19]. The time of peak
erum concentration was 4 h from AMI  onset, and the wash out
ate was higher than for other markers. Therefore the diagnostic
erformance of H-FABP might be reduced for AMI patients who are
dmitted later, and a single application of H-FABP has limitations
n the whole time-window diagnosis of AMI  [20]. The ROC-AUCs
f the all validated cardiac biomarkers in T3 were similar to those
n T6, in fact those of hs-TnT were 0. 988 (T3) and 0.989 (T6). That
f the absolute change in hs-TnT between T0 and T3 was enough
igh, therefore T6 sampling did not inﬂuence the diagnostic value
uring the clinical course.
To diagnose AMI  in the very early phase, other concept mark-
rs might be warranted. For example, matrix metalloproteinase-9,
oluble lectin-like oxidized low-density lipoprotein receptor-1 and
entraxin 3 which could be detectable immediately after AMI  onset,
owever, further validations are required to introduce them to clin-
cal practice [11,21,22].
tudy limitations and implications
There are a few limitations associated with this study. First, all
articipant institutions were tertiary centers equipped with coro-
ary care units, therefore patients with more severe conditions
ere likely to be included in this study. In fact, the study cohort had
 much higher prevalence of STEMI patients compared with previ-
us reports. In this study population, the renal function disturbance
id not necessarily inﬂuence the behavior of hs-TnT for diagnosis of
MI, however further investigation regarding the relation between
enal function and hs-TnT level should be needed.
The present study reﬂects the AMI  prevalence in the represen-
ative tertiary care centers in Japan, and the entry criteria of an
nitially negative TnT test would demonstrate both the diagnostic
erformance and limitations of hs-TnT for an earlier diagnosis of
MI.
onclusions
The present study, which reﬂected the contemporary real-world
f tertiary centers in Japan, demonstrated that the hs-TnT displayed
00% sensitivity and negative predictive value for the patients
dmitted more than 120 min  from the onset, however the speci-
city was limited. Furthermore, the absolute change in hs-TnT from
0 to T3 showed the highest diagnostic performance among the
arious validated markers for the diagnosis of AMI.
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